US Bancorp’s Gyre Therapeutics GYRE Stock Holding History

US Bancorp’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-98	Closed	-$683	–	4243
2026 Q1	$683	Buy	+98	New	+$761	﹤0.01%	3975
2025 Q2	–	Sell	-17	Closed	-$131	–	4228
2025 Q1	$131	Buy	+17	New	+$186	﹤0.01%	4128

Other funds holding GYRE

HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

US Bancorp's GYRE Position: Q2 2026 in Review

US Bancorp sold out of Gyre Therapeutics (GYRE) in Q2 2026, closing a stake of 98 shares — an estimated $683 sold.

US Bancorp first reported a position in GYRE in Q1 2025 and held it in 2 quarters. The position peaked at $683 in Q1 2026. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

US Bancorp reported no remaining Gyre Therapeutics position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 98 Gyre Therapeutics shares in Q2 2026, an estimated $683.
US Bancorp first reported a position in Gyre Therapeutics in Q1 2025 and held it in 2 quarters.
US Bancorp's Gyre Therapeutics position peaked at $683 in Q1 2026.
60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.